Penumbra, Inc. Stock price

Equities

PEN

US70975L1070

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
223.2 USD -1.41% Intraday chart for Penumbra, Inc. -1.92% -11.27%
Sales 2024 * 1.25B Sales 2025 * 1.45B Capitalization 8.76B
Net income 2024 * 108M Net income 2025 * 154M EV / Sales 2024 * 6.86 x
Net cash position 2024 * 217M Net cash position 2025 * 353M EV / Sales 2025 * 5.8 x
P/E ratio 2024 *
82 x
P/E ratio 2025 *
58 x
Employees 4,200
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.18%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.49%
1 week-4.23%
Current month-3.64%
1 month-2.56%
3 months-13.00%
6 months-5.95%
Current year-10.00%
More quotes
1 week
217.37
Extreme 217.365
227.58
1 month
217.37
Extreme 217.365
261.44
Current year
217.37
Extreme 217.365
277.34
1 year
180.93
Extreme 180.93
348.67
3 years
114.87
Extreme 114.865
348.67
5 years
114.87
Extreme 114.865
348.67
10 years
35.32
Extreme 35.315
348.67
More quotes
Managers TitleAgeSince
Founder 62 04-06-20
Chief Executive Officer 62 04-06-20
Director of Finance/CFO 52 19-12-01
Members of the board TitleAgeSince
Director/Board Member 60 17-01-12
Director/Board Member 57 15-03-31
Chief Executive Officer 62 04-06-20
More insiders
Date Price Change Volume
24-03-28 223.2 -1.41% 387 503
24-03-27 226.4 +2.49% 464,660
24-03-26 220.9 +0.35% 928,942
24-03-25 220.1 -2.07% 503,666
24-03-22 224.7 -1.24% 327,984

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Penumbra, Inc. is a global healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that focuses on medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. It has developed a product portfolio that includes seven product families within its major markets, in which its neuro products include Thrombectomy, Embolization, Access, and Neurosurgical Tools. Its vascular products include Thrombectomy and Embolization. The Company's immersive healthcare product is Immersive 3D Computer-based Technology Platform. The Company sells its products to hospitals and healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
226.4 USD
Average target price
280 USD
Spread / Average Target
+23.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Penumbra, Inc. - Nyse